Catalyst Oncology

When I embarked on this cancer journey a year and 7 months ago, I wrote about the terror of standing on a cliff, looking down and not being able to see what was at the bottom of the canyon. I knew I had to get down but I wasn’t quite sure how I would do it or what obstacles I would encounter along the way. Like any experienced hiker knows, the only way down is to start walking, so that’s what I did, taking each obstacle as it came into view on my path –surgery, chemo, heart problems, my childr

View original post here: 
We Make Our Own Parades

Lenalidomide is an immunomodulatory drug and a structural analogue of thalidomide which has been developed by Celgene. Potential clinical applications investigated for lenalidomide include CNS cancer, inflammation, malignant melanoma, chronic lymphocytic leukaemia, myelodysplastic syndromes, and multiple myeloma (MM). REVLIMID® (lenalidomide) in combination with dexamethasone is indicated for the treatment of multiple myeloma patients who have received at least one prior therapy. The consensus

Read the rest here:
Revlimid for myeloma - first line.

CancerCare of New Jersey invites golfers to spend a day on the greens at one of the Garden State’s top golf courses for our 23rd Annual Golf Invitational. The event will be held at Essex County Country Club (ECCC) on Monday, August 10, 2009, and will support CancerCare’s free programs and services for people affected by cancer. Located in West Orange, ECCC is the oldest country club in New Jersey, rich in history and tradition.  The private club is also known for its long and challenging c

View original here: 
CancerCare’s 23rd Annual Golf Invitational

Great Western Bank donated $750 to the Summit Healthcare Foundation to provide assistance to oncology patients by providing gas cards and prescription vouchers to them.

Read the original post:
WMICentral - Bank helps out oncology department with donation

A media release issued last Wednesday from the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, and based on data presented at the recent annual meeting of the American Society for Clinical Oncology (ASCO), is suggesting that it is possible to predict, with greater accuracy, the long-term risk of metastatic disease in men treated surgically for supposedly localized prostate cancer.The data on which this media release is based were presented at the ASCO meeting by Antonarakis et al., a

See original here:
Risk for metastasis post-surgery: a prognostic algorithm

Credits: ReutersBy Michael PerrySYDNEY (Reuters) – Australian scientists have developed a “trojan horse” therapy to combat cancer, using a bacterially-derived nano cell to penetrate and disarm the cancer cell before a second nano cell kills it with chemotherapy drugs.The “trojan horse” therapy has the potential to directly target cancer cells with chemotherapy, rather than the current treatment that sees chemotherapy drugs injected into a cancer patient and attacking both cancer and healthy cell

Here is the original:
Scientists kill cancer cells with “trojan horse”

In the study, researchers at The Mount Sinai Medical Center Departments of Radiation Oncology and Urology in New York followed 742 prostate cancer patients who were treated with brachytherapy alone, brachytherapy and hormonal therapy, …

Go here to see the original: 
Prostate Cancer Patients Are Recurrence Free After 5 Years …

Graceway Pharmaceuticals obtained commercialization rights to three dermatological molecules from Pfizer. The acquisition and license agreement includes related transferred or licensed intellectual properties. This transaction is part of Pfizer’s plan to out-license noncore programs; the firm identified CNS diseases, oncology, and cardiovascular diseases as its focus. Pfizer continues to be responsible, however, for performing developmental and clinical services for these three molecules.

Go here to read the rest:
Graceway Acquires Dermatological Compounds from Pfizer

Author : Gregory Smyth Women in the US have around a 1 in 8 chance of developing breast cancer at some stage in their lives, and a three percent chance of dying from it Breast cancer is the leading cause of cancer death among women the world over, and is second only to heart disease in total numbers of deaths caused Treatment of breast cancer is an extremely important issue - yet many women do not know their treatment options for breast cancer What do most women know about treating breast

Read more: 
What Women Know About Breast Cancer Treatment Options

Diet and Exercise Improves Functionality in Older, Overweight … American Journal of Hemotology and Oncology Older cancer survivors who are overweight can use diet and exercise to slow functional decline, say researchers at Duke University School of Medicine. … and more »

Go here to read the rest: 
Diet and Exercise Improves Functionality in Older, Overweight … - American Journal of Hemotology and Oncology